Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB5673 : Y-MESO-28  update : 2025/01/30
Comment
Comment from the depositorHuman pleural mesothelioma cell line. This cell line was established from the pleural effusion of epithelioid mesothelioma of a patient.
Terms and conditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Cancer Res 2011 71(3):873-83) designated by the DEPOSITOR is requested.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor SEKIDO, Yoshitaka
Originator SEKIDO, Yoshitaka
Year of deposit 2022
Cloning (depositor) No
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 65 years
Tissue pleural effusion
Primary focus pleural mesothelioma
Disease name pleural mesothelioma
Tumor pleural mesothelioma, epithelioid
Classification cancer
Recombinant non-recombinant
Year of origin 2007
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_5185
deposit info
lot info
Medium Medium List
Culture type Adherent cells Adherent cells
Culture medium RPMI1640 + 10% FBS RPMI1640 + 10% FBS
Antibiotics 1% antimicrobial Free
Passage method 0.25w/v% Trypsin + 1mmol/l EDTA（FUJIFILM 209-16941） 0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
Culture information Passage ratio 1 : 5-8 split 1 : 3 split
SC frequency Subculture : 1-2 times/week Subculture : 1-2 times/week
Temperature 37 ℃ 37 ℃
CO2 concentration 5 % 5 %
Freeze medium CELLBANKER CELLBANKER 1
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Mycoplasma (-)
Animal PCR OK
STR(human) OK
deposit info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11,12 8 11 9 14,16 9 X,Y 10 10,12
lot info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11,12 8 11 9 14,16 9 X,Y 10 10,12
Reference information Reference 11
User's Publication 0


To topTop
Reference
16476  Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, Tsuji Y, Hamaguchi K, Yasunaga M, Nishiya Y, Suzuki M, Saito JI, Yatsunami R, Nakamura S, Sekido Y, Mori K.  The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma  Am J Cancer Res  2020  ;10(12):4399-4415  PubMed ID: 33415007  
16027  Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation  Oncogene  2018  38(11):1966-1978  PubMed ID: 30401981   DOI: 10.1038/s41388-018-0417-7
16467  Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.  Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis  Cancer Lett  2017  385:215-224.  PubMed ID: 27773750   DOI: 10.1016/j.canlet.2016.10.020
16477  Kato T, Sato T, Yokoi K, Sekido Y.  E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells  Oncogene  2017  36(39):5522-5531  PubMed ID: 28553954   DOI: 10.1038/onc.2017.147
16468  Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, Sekido Y.  Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells  Cancer Sci  2015  106(8):990-9.  PubMed ID: 26011428   DOI: 10.1111/cas.12698
16469  Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.  LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade  Oncogene  2015  34(1):73-83  PubMed ID: 24336325   DOI: 10.1038/onc.2013.528
16471  Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, Sekido Y.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes  Oncogene  2012  31(49):5117-22  PubMed ID: 22286761   DOI: 10.1038/onc.2012.5
16472  Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Yokoi K, Osada H, Sekido Y.  Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma  J Thorac Oncol  2012  7(5):890-9  PubMed ID: 22722789   DOI: 10.1097/JTO.0b013e31824af2db
16474  Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y.  LATS2 is a tumor suppressor gene of malignant mesothelioma  Cancer Res  2011  71(3):873-83  PubMed ID: 21245096   DOI: 10.1158/0008-5472.CAN-10-2164
16457  Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y.  Activation of the PI3K-AKT pathway in human malignant mesothelioma cells  Mol Med Rep  2009  2(2):181-8  PubMed ID: 21475810   DOI: 10.3892/mmr_00000081
16475  Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y.  Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells  Carcinogenesis  2009  30(7):1097-105  PubMed ID: 19380521   DOI: 10.1093/carcin/bgp097

To topTop
User's Publication


Back Back Return Top Page